Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (SHE:002864)
35.38
+0.03 (0.08%)
Feb 4, 2026, 3:04 PM CST
SHE:002864 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,096 | 971.45 | 978.2 | 971.04 | 883.76 | 667.66 |
Other Revenue | 2.41 | 2.41 | 2.63 | 3.26 | 3.73 | 2.66 |
| 1,098 | 973.86 | 980.83 | 974.29 | 887.48 | 670.31 | |
Revenue Growth (YoY) | 11.91% | -0.71% | 0.67% | 9.78% | 32.40% | 9.77% |
Cost of Revenue | 505.81 | 381.74 | 413.74 | 408.25 | 370.36 | 255.52 |
Gross Profit | 592.58 | 592.12 | 567.09 | 566.04 | 517.12 | 414.79 |
Selling, General & Admin | 420.6 | 436.86 | 418.79 | 416.11 | 386.15 | 305.6 |
Research & Development | 37.79 | 37.54 | 20.26 | 18.23 | 14.03 | 12.97 |
Other Operating Expenses | 16.45 | 9.35 | 10.61 | 10.23 | 9.29 | 7.15 |
Operating Expenses | 480.17 | 485.59 | 453.98 | 452.94 | 414.07 | 329.39 |
Operating Income | 112.41 | 106.53 | 113.11 | 113.1 | 103.05 | 85.39 |
Interest Expense | -1.31 | -1.56 | -6.11 | -13.92 | -3.49 | -2.85 |
Interest & Investment Income | 20.09 | 25.58 | 22.06 | 17.18 | 11.78 | 8.32 |
Other Non Operating Income (Expenses) | -4.99 | -0.22 | 0.31 | 2.55 | -5.27 | 1.19 |
EBT Excluding Unusual Items | 126.2 | 130.32 | 129.37 | 118.91 | 106.06 | 92.06 |
Gain (Loss) on Sale of Investments | -0 | - | -1.56 | -0.11 | - | - |
Gain (Loss) on Sale of Assets | 0.12 | -0.01 | 0.17 | - | - | 0.15 |
Asset Writedown | -0.38 | -0.18 | -0.81 | -0.08 | -0 | -0.19 |
Other Unusual Items | 16.15 | 6.82 | 2.08 | 0.46 | 2.97 | 2.49 |
Pretax Income | 142.08 | 136.95 | 129.25 | 119.18 | 109.03 | 94.5 |
Income Tax Expense | 21.84 | 17.03 | 17.7 | 16.03 | 14.47 | 13.4 |
Earnings From Continuing Operations | 120.24 | 119.92 | 111.55 | 103.15 | 94.56 | 81.09 |
Minority Interest in Earnings | 0.26 | 0.35 | -1.11 | -1.98 | -1.39 | -1.98 |
Net Income | 120.51 | 120.27 | 110.43 | 101.16 | 93.17 | 79.12 |
Net Income to Common | 120.51 | 120.27 | 110.43 | 101.16 | 93.17 | 79.12 |
Net Income Growth | 3.97% | 8.91% | 9.16% | 8.58% | 17.77% | 10.22% |
Shares Outstanding (Basic) | 105 | 105 | 96 | 86 | 85 | 86 |
Shares Outstanding (Diluted) | 105 | 105 | 98 | 86 | 85 | 86 |
Shares Change (YoY) | -2.47% | 7.02% | 13.03% | 1.16% | -0.60% | -0.56% |
EPS (Basic) | 1.15 | 1.15 | 1.15 | 1.18 | 1.09 | 0.92 |
EPS (Diluted) | 1.15 | 1.15 | 1.13 | 1.17 | 1.09 | 0.92 |
EPS Growth | 6.61% | 1.77% | -3.42% | 7.34% | 18.48% | 10.84% |
Free Cash Flow | 45.13 | 74.54 | 41.53 | 69.53 | 35.36 | 21.06 |
Free Cash Flow Per Share | 0.43 | 0.71 | 0.42 | 0.80 | 0.41 | 0.24 |
Dividend Per Share | 0.350 | 0.250 | 0.220 | 0.200 | 0.180 | 0.150 |
Dividend Growth | 59.09% | 13.64% | 10.00% | 11.11% | 20.00% | - |
Gross Margin | 53.95% | 60.80% | 57.82% | 58.10% | 58.27% | 61.88% |
Operating Margin | 10.23% | 10.94% | 11.53% | 11.61% | 11.61% | 12.74% |
Profit Margin | 10.97% | 12.35% | 11.26% | 10.38% | 10.50% | 11.80% |
Free Cash Flow Margin | 4.11% | 7.65% | 4.23% | 7.14% | 3.98% | 3.14% |
EBITDA | 146.91 | 139.02 | 142.92 | 130.16 | 117.8 | 99.85 |
EBITDA Margin | 13.38% | 14.27% | 14.57% | 13.36% | 13.27% | 14.89% |
D&A For EBITDA | 34.5 | 32.49 | 29.81 | 17.07 | 14.74 | 14.45 |
EBIT | 112.41 | 106.53 | 113.11 | 113.1 | 103.05 | 85.39 |
EBIT Margin | 10.23% | 10.94% | 11.53% | 11.61% | 11.61% | 12.74% |
Effective Tax Rate | 15.37% | 12.43% | 13.70% | 13.45% | 13.27% | 14.19% |
Revenue as Reported | 1,098 | 973.86 | 980.83 | 974.29 | 887.48 | 670.31 |
Advertising Expenses | - | 5.04 | 1.09 | 1.76 | 3.68 | 0.62 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.